These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 32762993)

  • 1. A Review of the Methods Used to Generate Utility Values in NICE Technology Assessments for Children and Adolescents.
    Hill H; Rowen D; Pennington B; Wong R; Wailoo A
    Value Health; 2020 Jul; 23(7):907-917. PubMed ID: 32762993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease.
    Moore A; Young CA; Hughes DA
    Value Health; 2018 Nov; 21(11):1322-1329. PubMed ID: 30442280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping the COPD Assessment Test onto EQ-5D.
    Hoyle CK; Tabberer M; Brooks J
    Value Health; 2016 Jun; 19(4):469-77. PubMed ID: 27325339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the relationship between preference-based generic utility instruments and disease-specific quality-of-life measures in severe chronic constipation: challenges in practice.
    Parker M; Haycox A; Graves J
    Pharmacoeconomics; 2011 Aug; 29(8):719-30. PubMed ID: 21635017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The estimation of health state utility values in rare diseases: do the approaches in submissions for NICE technology appraisals reflect the existing literature? A scoping review.
    Meregaglia M; Nicod E; Drummond M
    Eur J Health Econ; 2023 Sep; 24(7):1151-1216. PubMed ID: 36335234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals.
    Tosh JC; Longworth LJ; George E
    Value Health; 2011 Jan; 14(1):102-9. PubMed ID: 21211492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What value health?: A review of health state values used in early technology assessments for NICE.
    Stein K; Fry A; Round A; Milne R; Brazier J
    Appl Health Econ Health Policy; 2005; 4(4):219-28. PubMed ID: 16466273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
    Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
    Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines.
    Kennedy-Martin M; Slaap B; Herdman M; van Reenen M; Kennedy-Martin T; Greiner W; Busschbach J; Boye KS
    Eur J Health Econ; 2020 Nov; 21(8):1245-1257. PubMed ID: 32514643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EQ-5D-Y Value Set for Germany.
    Kreimeier S; Mott D; Ludwig K; Greiner W;
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):217-229. PubMed ID: 35604633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The EQ-5D-5L Valuation study in Thailand.
    Pattanaphesaj J; Thavorncharoensap M; Ramos-Goñi JM; Tongsiri S; Ingsrisawang L; Teerawattananon Y
    Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):551-558. PubMed ID: 29958008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals.
    Pennington B; Hernandez-Alava M; Pudney S; Wailoo A
    Pharmacoeconomics; 2019 Jan; 37(1):75-84. PubMed ID: 30094806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health utility estimation in children and adolescents: a review of health technology assessments.
    Bégo-Le Bagousse G; Jia X; Wolowacz S; Eckert L; Tavi J; Hudson R
    Curr Med Res Opin; 2020 Jul; 36(7):1209-1224. PubMed ID: 32345060
    [No Abstract]   [Full Text] [Related]  

  • 14. Inclusion of Carer Health-Related Quality of Life in National Institute for Health and Care Excellence Appraisals.
    Pennington BM
    Value Health; 2020 Oct; 23(10):1349-1357. PubMed ID: 33032779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating an exchange rate between the EQ-5D-3L and ASCOT.
    Stevens K; Brazier J; Rowen D
    Eur J Health Econ; 2018 Jun; 19(5):653-661. PubMed ID: 28623464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective.
    Kreimeier S; Oppe M; Ramos-Goñi JM; Cole A; Devlin N; Herdman M; Mulhern B; Shah KK; Stolk E; Rivero-Arias O; Greiner W
    Value Health; 2018 Nov; 21(11):1291-1298. PubMed ID: 30442276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EQ-5D-Y as a Health-Related Quality of Life Instrument for Children and Adolescents: The Instrument's Characteristics, Development, Current Use, and Challenges of Developing Its Value Set.
    Kreimeier S; Greiner W
    Value Health; 2019 Jan; 22(1):31-37. PubMed ID: 30661631
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.